NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

SINGLE TECHNOLOGY APPRAISAL

Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane [ID603]

The following documents are made available to the consultees and commentators:

1. **Appeal Decision**

2. **NICE position statement to the Pharmaceutical Price Regulation Scheme 2014**

3. **Response to position statement from Roche Products**

Any information supplied to NICE which has been marked as confidential, has been redacted. All personal information has also been redacted.